Farnsworth W E, Gonder M J, Cartagena R, Steinbach J J
Urology. 1980 Aug;16(2):165-7. doi: 10.1016/0090-4295(80)90074-6.
Three commercial radioimmunoassays and one enzymatic assay for prostatic acid phosphatase (PAP) have been tested on 122 patients to determine their relative specificity, sensitivity, and diagnostic value. Each of the three radioimmunoassays was found to have special merits. For distinguishing Stage IV prostatic cancer from normal patients without prostatic disease, the Smith Kline (SKF) and New England Nuclear (NEN) assays provide more significant differences. The SKF test also best distinguishes all stages of prostatic cancer from benign prostatic hyperplasia (BPH), but is inferior to the Malinckrodt (MAL) assay for contrasting Stage IV prostatic cancer from BPH. Values obtained with the NEN assay best distinguish the stages of prostatic cancer. Only with the MAL assay are significantly higher PAP values obtained in patients with metastases to bone than those without positive bone scans. Viewed from the point of sensitivity, the SKF assay proves best at all levels of specificity examined in detecting all stages (I-IV), and Stage IV prostatic cancer. By none of the assays can estrogenized Stage III and IV cancer patients be distinguished from those not on estrogen.
已对122例患者进行了三种市售前列腺酸性磷酸酶（PAP）放射免疫测定法和一种酶法测定，以确定它们的相对特异性、敏感性和诊断价值。发现三种放射免疫测定法各有其优点。对于区分IV期前列腺癌与无前列腺疾病的正常患者，史克必成（SKF）和新英格兰核公司（NEN）的测定法提供了更显著的差异。SKF检测在区分前列腺癌各期与良性前列腺增生（BPH）方面也表现最佳，但在区分IV期前列腺癌与BPH方面不如马林克罗特（MAL）测定法。用NEN测定法获得的值最能区分前列腺癌的分期。只有MAL测定法显示，骨转移患者的PAP值明显高于骨扫描无阳性结果的患者。从敏感性来看，在检测所有分期（I-IV期）及IV期前列腺癌时，在所检测的所有特异性水平上，SKF测定法被证明是最佳的。没有一种测定法能够区分接受雌激素治疗的III期和IV期癌症患者与未接受雌激素治疗的患者。
